Expression and clinical significance of methylenetetrahydrofolate reductase in patients with colorectal cancer

Clinical Colorectal Cancer

Volumn 5, Issue 5, 2006, Pages 344-349

  Odin, Elisabeth ^a,d   Wettergren, Yvonne ^a   Carlsson, Göran ^a   Danenberg, Peter V ^b   Termini, Angelo ^a   Willén, Roger ^c   Gustavsson, Bengt ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

C677T; Folate; Folylpolyglutamate synthase; Thymidylate synthase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR CLASSIFICATION;

EID: 33244474447     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.004     Document Type: Article

References (44)

1. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
2. Kang SS, Zhou J, Wong PW, et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43:414-421.
3. Zittoun J, Tonetti C, Bories D, et al. Plasma homocysteine levels related to interactions between folate status and methylenetetrahydrofolate reductase: a study in 52 healthy subjects. Metabolism 1998; 47:1413-1418.
4. Stern LL, Mason JB, Selhub J, et al. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 2000; 9:849-853.
5. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 2002; 99:5606-5611.
6. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57:1098-1102.
7. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56:4862-4864.
8. Delgado-Enciso I, Martinez-Garza SG, Rojas-Martinez A, et al. 677T mutation of the MTHFR gene in adenomas and colorectal cancer in a population sample from the Northeastern Mexico. Preliminary results. Rev Gastroenterol Mex 2001; 66:32-37.
9. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 1999; 8:659-668.
10. Ryan BM, Molloy AM, McManus R, et al. The methylenetetrahydrofolate reductase (MTHFR) gene in colorectal cancer: role in tumor development and significance of allelic loss in tumor progression. Int J Gastrointest Cancer 2001; 30:105-111.
11. Hustad S, Ueland PM, Vollset SE, et al. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000; 46:1065-1071.
12. Spears CP, Hayes AA, Shahinian AH. et al. Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate- folate ternary complex formation. Biochem Pharmacol 1989; 38:2985-2993.
13. Spears CP, Gustavsson BG, Mitchell MS, et al. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 1984; 44:4144-4150.
14. Cohen V, Panet-Raymond V, Sabbaghian N, et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9:1611-1615.
15. Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm 1989; 45:263-335.
16. Boarman DM, Allegra CJ. Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res 1992; 52:36-44.
17. Danenberg PV, Danenberg KD. Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 1978; 17:4018-4024.
18. Radparvar S, Houghton PJ, Houghton JA. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 1989; 38:335-342.
19. Odin E, Wettergren Y, Nilsson S, et al. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003; 9:6012-6019.
20. Jothy S, Slesak B, Harlozinska A, et al. Field effect of human colon carcinoma on normal mucosa: relevance of carcinoembryonic antigen expression. Tumour Biol 1996; 17:58-64.
21. Terpstra OT, van Blankenstein M, Dees J, et al. Abnormal pattern of cell proliferation in the entire colonic mucosa of patients with colon adenoma or cancer. Gastroenterology 1987; 92:704-708.
22. Shamsuddin AK, Weiss L, Phelps PC, et al. Colon epithelium. IV. Human colon carcinogenesis. Changes in human colon mucosa adjacent to and remote from carcinomas of the colon. J Natl Cancer Inst 1981; 66:413-419.
23. Mason JB, Levesque T. Folate: effects on carcinogenesis and the potential for cancer chemoprevention. Oncology (Williston Park) 1996; 10:1727-1736, 1742-1743; discussion 1743-1744.
24. Hamilton SR, Aaltonen L. WHO classification of tumors. Pathology and genetics. Tumours of the digestive system. Lyon, France: IARC press; 2000:104.
25. Astler V, Coller F. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954; 139:846-852.
26. Beart RW Jr, van Heerden J, Beahrs O. Evolution in the pathologic staging of carcinoma of the colon. Surg Gynecol Obstet 1978; 146:257-259.
27. Dukes C. The classification of cancer of the rectum. J Pathol 1932; 35:323-332.
28. Flemming I, ed. American Joint Committee on Cancer Staging Manual. 5th ed. Philadelphia: J. A. Majors Company; 1997.
29. ABI PRISM 7700 Sequence Detection Systems [User Bulletin #2]. Foster City, CA: Applied Biosystems; 1997:1-36.
30. TaqMan Universal PCR Master mix, Biosystems A. 1998.
31. Priest DG, Bunni M, Sirotnak FM. Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo. Cancer Res 1989; 49:4204-4209.
32. Spears CP, Gustavsson BG. Methods for thymidylate synthase pharmacodynamics: serial biopsy, free and total TS, FdUMP and dUMP, and H4PteGlu and CH2-H4PteGlu assays. Adv Exp Med Biol 1988; 244:97-106.
33. JMP Statistical Discovery [computer program]. 4 edition. Cary, NC: SAS Institute; 2000.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
35. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci U S A 1998; 95:13217-13220.
36. Kawakami K, Ruszkiewicz A, Bennett G, et al. The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 2003; 9:5860-5865.
37. Priest DG, Raghunathan K, Liu Y, et al. Modulation of thymidylate synthase expression by dietary folic acid induced DNA hypomethylation in a mouse model tumor. In: Pfeiderer, Rokos, eds. Chemistry and Biology of Pteridines and Folates. Berlin: Blackwell Scientific; 1997:387-392.
38. Cravo M, Fidalgo P, Pereira AD, et al. DNA methylation as an intermediate biomarker in colorectal cancer: modulation by folic acid supplementation. Eur J Cancer Prev 1994; 3:473-479.
39. Brabender J, Marjoram P, Lord RV, et al. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005; 14:2113-2137.
40. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFDI genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4:66-72.
41. Guenther BD, Sheppard CA, Tran P, et al. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 1999; 6:359-365.
42. Moat SJ, Ashfield-Watt PA, Powers HJ, et al. Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype. Clin Chem 2003; 49:295-302.
43. Lathrop Stern L, Shane B, Bagley PJ, et al. Combined marginal folate and riboflavin status affect homocysteine methylation in cultured immortalized lymphocytes from persons homozygous for the MTHFR C677T mutation. J Nutr 2003; 133:2716-2720.
44. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.